CareDx is a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy that just completed two transformative transactions in a single quarter, and the question for the next twelve months is whether the company can sustain the 52 percent Q2 2026 revenue growth and the CMS Medicare coverage finalization as the foundation for the next leg of profitable growth. The Q2 2026 print was the cleanest test yet of that thesis, and the cleanest signal is that the company divested the Lab Products business to Eurobio Scientific on June 30, 2026, recognizing a $113 million gain on sale, and closed the acquisition of Naveris (specialty oncology diagnostics), reshaping the company into a pure precision molecular diagnostics platform. The combination of the $132 million of Q2 2026 revenue up 52 percent year over year, the $100 million of Testing Services revenue up 61 percent year over year, the 58,000 Testing Services volume up 17 percent year over year, the $19 million of Patient and Digital Solutions revenue up 50 percent year over year, the $13 million of Lab Product revenue up 8 percent year over year, the $1,720 average revenue per test including $16 million in prior period revenue, the $111 million of Q2 2026 GAAP net income versus a $9 million GAAP net loss in Q2 2025, the $2.15 basic and $2.07 diluted Q2 2026 GAAP net income per share, the $25 million of Q2 2026 Adjusted EBITDA versus $5 million in Q2 2025, the $31 million of Q2 2026 cash flow from operations, the Lab Products divestiture to Eurobio Scientific closed on June 30, the Naveris acquisition closed, the CMS finalized Medicare coverage policy for AlloSure and AlloMap, the AlloHeme pipeline program CLIA readiness progress, the HistoMap Kidney data in Transplantation, the AHNS Annual Meeting NavDx data, the ATC AlloSure data, the KOAR data in JASN, the $490 million to $500 million raised 2026 revenue guidance, and the $66 million to $78 million raised 2026 AEBITDA guidance is the cleanest single read on what the Naveris-integration pivot is producing. The strategic tension is the Lab Products divestiture revenue elimination against the Testing Services revenue acceleration and the Naveris integration contribution, and the forward question is whether the company can sustain the 52 percent revenue growth and the $66 million to $78 million AEBITDA guidance as the foundation for the next leg of profitable growth.